The New York Times reports many voters still face higher prescription and insurance costs.
President Trump has been promoting his efforts to cut drug prices, but many Americans still are not seeing that relief at the pharmacy counter or in their insurance premiums, according to The New York Times.
That is a stubborn problem for any White House trying to sell affordability as a lived reality rather than a line item. Prescription costs are intimate in a way many economic arguments are not: people notice them in monthly refills, at checkout screens and in the arithmetic that turns a treatment into a household stress test.
The Times says voters continue to face rising costs for prescriptions and insurance, undercutting the administration’s message on drug pricing. Based on the available summary, the report focuses less on a single policy announcement than on the gap between presidential promotion and patient experience.
Politically, that gap matters because drug prices are one of the few cost-of-living issues that feel both highly personal and brutally repetitive. A speech can promise discipline; a premium notice has its own style of persuasion.
The summary does not specify which policies Trump highlighted or which medicines and plans are driving the pressure, so the clearest supported fact is also the most damaging one: many Americans are still paying more.
Isla Camilleri
Sophia Borg
Alex de Valletta